LUNELORD: A Descriptive, Prospective Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and QoL of Patients With LUpus NEphritis and Long-term ORgan Damage
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates \[UAE\], Qatar, Bahrain, Kuwait and Oman).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• More than or equal to 18 years of age
• Clinician diagnosed LN participants.
• At least one visit to the investigational center during 12 months prior to the baseline visit, recorded in medical documentation.
• Literacy in English or Arabic allowing to fully comprehend the written informed consent and study-specific patient reported questionnaires.
Locations
Other Locations
United Arab Emirates
GSK Investigational Site
RECRUITING
Dubai
Contact Information
Primary
US GSK Clinical Trials Call Center
GSKClinicalSupportHD@gsk.com
877-379-3718
Backup
EU GSK Clinical Trials Call Center
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
Time Frame
Start Date: 2021-09-14
Estimated Completion Date: 2024-10-31
Participants
Target number of participants: 200
Treatments
Participants with Lupus Nephritis
Related Therapeutic Areas
Sponsors
Leads: GlaxoSmithKline